Generated by AI
Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on rare diseases. Its current business centers on developing and commercializing therapies for patients with serious conditions that have limited or no treatment options, with approved products and late-stage assets spanning Niemann-Pick disease type C, urea cycle disorders, and related neurological and metabolic disorders. The company’s portfolio includes marketed medicines, active clinical programs, and partnership-derived royalty interests, reflecting a model that combines direct product commercialization with pipeline development. Zevra Therapeutics also uses its Ligand Activated Technology platform to support product development. Headquartered in the United States, Zevra Therapeutics plays a focused role in the rare disease market by advancing specialized treatments for patient populations with significant unmet medical needs.
Website101 Federal Street
Boston, MA, 02110
United States
The latest articles about ZVRA.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 13's posts. Generated by AI.
Summary of Mar 10's posts. Generated by AI.
Summary of Nov 13's posts. Generated by AI.
Investors talking about ZVRA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.